Concerns about acceptable production practices at Catalent's syringe filling facility is the reason why Novo Nordisk is now only expected to be able to fully meet Wegovy demand in the second half of 2022, according to media Bioprocess International.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Sonova completes Hysound Group acquisition, strengthens presence in China
The hearing aid giant now owns over 200 hearing clinics in China.
Extra data boosts Lundbeck's agitation case
Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.
FDA confirms rejection of Y-mabs' cancer drug
The US Food and Drug Administration has officially rejected a Y-mabs cancer drug, after it was voted down by a sub-committee in October.
Top news from MedWatch this week
Miss anything?
Ambu, Coloplast and GN helped by relaxation of China's covid policy
The three firms, which all have production facilities in the country, appear to be benefitting from the relaxation of China’s zero-tolerance Covid-19 policy.
Research Scientist (maternity cover) 
Nordic Medical Manager, Central Nervous System 
Principal Systems Engineer 
Strategic advisor and negotiator with in-depth knowledge of the pharmaceutical market 
Director, QA Commercial Drug Substance, Ascendis Pharma 
Supply Chain Manager 
Associate Director, Global Drug Safety and Pharmacovigilance Scientist 
Head of Engineering 
Quality Assurance Specialist (QAS) in dietary supplements 
Chief consultant for Dansk Erhvervs Health and life science 
Laboratory assistants for an exciting QC department